• Publications
  • Influence
Risk of Ovarian Cancer Relapse Score
Objective The aim of this study was to construct a prognostic index that predicts risk of relapse in women who have completed first-line treatment for ovarian cancer (OC). Methods A database of OCExpand
  • 29
  • 3
Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.
BACKGROUND The use of assisted reproductive techniques is increasing, but the possible link between fertility drugs and ovarian cancer remains controversial. OBJECTIVES To evaluate the risk ofExpand
  • 79
  • 1
The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.
BACKGROUND Penetrance for breast cancer, ovarian cancer, or both in carriers of BRCA1/BRCA2 mutations is disproportionately high. Sex hormone dysregulation and altered end-organ hormone sensitivityExpand
  • 79
  • 1
  • PDF
Beyond Guidelines: Effectiveness of a Programme in Achieving Operative Laparoscopy for all Women Requiring Surgical Management of Ectopic Pregnancy
Background/Aims: Operative laparoscopy (OL) is considered the gold standard surgical treatment of ectopic pregnancy (EP). We questioned whether a training programme to foster OL treatment is able toExpand
  • 8
  • 1
Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study
Purpose To establish the performance of screening with serum cancer antigen 125 (CA-125), interpreted using the risk of ovarian cancer algorithm (ROCA), and transvaginal sonography (TVS) for women atExpand
  • 68
  • PDF
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
BackgroundCombined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy.MethodsThis dose-finding phase Ib study (adaptive 3 + 3 design) determinedExpand
  • 17
  • PDF
Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.
2514 Background: NUC-1031 is a first-in-class nucleotide analogue utilising phosphoramidate chemistry to enhance anti-cancer efficacy and safety. In preclinical studies NUC-1031 demonstrated potentExpand
  • 8
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
BackgroundGemcitabine is used to treat a wide range of tumours, but its efficacy is limited by cancer cell resistance mechanisms. NUC-1031, a phosphoramidate modification of gemcitabine, is the firstExpand
  • 14
Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.
Gemcitabine is an anticancer agent acting against several solid tumors. It requires nucleoside transporters for cellular uptake and deoxycytidine kinase for activation into activeExpand
  • 10